Multiple Ascending Dose, Phase 1 Clinical Study of LCB01-0371

Phase 1 Completed 30 enrolled LigaChem Biosciences, Inc.

RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the population pharmacokinetics of LCB01-0371 after a multiple oral dose in healthy male subjects. To investigate safety, tolerability of LCB01-0371 after a multiple oral dose in healthy male subjects.

Timeline

Start: 2014-06
Primary completion: 2014-12
Completion: 2015-01

Publications

Choi Y, Lee SW, Kim A, Jang K, Nam H, Cho YL, Yu KS, Jang IJ, Chung JY. Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjects. J Antimicrob Chemother. 2018 Jan 1;73(1):183-190. doi: 10.1093/jac/dkx367.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Delpazolid	Small molecule	800 mg	Oral
Subject	Delpazolid	Small molecule	1200 mg	Oral

Indications

No indication recorded.